Elana Rosenthal
Infectious Disease · Baltimore, MDNPI 1679893390
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,740 of the $1,782 with a category attached, or 97.6%. Every reported general payment came from a single manufacturer, Gilead.
Across 2 payments — averaging $891.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
Across 8 payments — averaging $204,408 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.5M
- Gilead$67K
- Adamis Pharmaceuticals Corporation$55K
What the payments were for
- Consulting fees$1,74098%
- Food & beverage$422%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 2 | $1,782 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epclusa$1,740
How this compares
$1,782 in reported general payments places this provider in the 70th percentile of 289 infectious disease providers in Maryland.
Other infectious disease in Baltimore
- Robert RedfieldBaltimore$779K
- Luciana BorioBaltimore$671K
- Mark SulkowskiBaltimore$240K
- Jonathan ZenilmanBaltimore$202K
- Robert EdelmanBaltimore$125K
- Kjell WibergBaltimore$113K
- Christine DurandBaltimore$53K
- Myron LevineBaltimore$51K
- Robert BollingerBaltimore$50K
- Richard BergBaltimore$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.